According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have ...

Edesa Biotech has announced positive results from a Phase III clinical trial of its drug candidate, paridiprubart (EB05), for ...

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

Food and Drug Administration on Wednesday said it is aiming to reduce the number of human clinical studies required for ...

Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war ...

Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're ...

The upcoming EU Biotech Act may be more prominently focused on health. But it will also significantly impact food and food ...

Intellia Therapeutics is featured in Cathie Wood's portfolio and has a high Wall Street price target. The company's leading candidates look somewhat promising, but one of them just hit a major setback ...

In this episode, Fierce Biotech’s Darren Incorvaia and Gabrielle Masson came together to chat about themes from this year’s ...

Importantly, BGE-102 is an oral candidate. The current leaders in the anti-obesity market are administered via subcutaneous ...

Editor’s Note: This deep dive was originally published Sept. 24, 2025, as a special edition of Biopharm Executive. Subscribe ...

I agree to the Terms of Use , Privacy Notice and Cookie Notice. I agree to the Terms of Use , Privacy Notice and Cookie ...